Validation study of the recurrence risk stratification using 55-gene classifier (55GC) and RAS mutation in StageII/III colon cancer
Not Applicable
- Conditions
- Colon Cancer
- Registration Number
- JPRN-UMIN000023879
- Lead Sponsor
- ational Defense Medical College and Kyushu University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 1000
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Patients who had received preoperative therapy. (2) Patients with a previous malignancy, within 5 years of operation, except for tumors at the stage of carcinoma in situ. (3) Patients who had recurrence or died within 60 days of surgery.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To examine the relationship between recurrence risk stratification using 55-gene classifier (55GC) and RAS mutation, and recurrence-free, disease-free or overall survival in stage II and stage III colon cancer cases.
- Secondary Outcome Measures
Name Time Method To examine the significance of clinicopathological factors, gene mutations, and multiplex genomic tests as predictors of colon cancer recurrence risk. To investigate the novelty and independence of the 55-gene classifier and RAS family mutation as a risk factor. To examine whether novel procedures can evaluate the effect of oxaliplatin-based adjuvant chemotherapy.